Drugs / XL844
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00475917 | May 2007 → Dec 2008 | cancer, lymphoma | Exelixis | Terminated | No outcome recorded |
| Phase 1 | NCT00234481 | — | chronic lymphocytic leukemia/small lymphocytic lymphoma | Exelixis | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XL844 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00234481 ↗ |
| Action | Inhibit | “Serine/threonine-protein kinase Chk2 inhibitor” CHEMBL3544936 ↗1“Serine/threonine-protein kinase Chk1 inhibitor” CHEMBL3544936 ↗ |
| Route | Oral | “XL844 Administered Orally to Subjects With Chronic Lymphocytic Leukemia” NCT00234481 ↗ |
| Target | CHEK1 | “Serine/threonine-protein kinase Chk1 inhibitor” CHEMBL3544936 ↗ |
| Target | CHEK2 | “Serine/threonine-protein kinase Chk2 inhibitor” CHEMBL3544936 ↗ |